ChIP-sequencing profiles for H3K4me3, H3K27me1 and H3K27me3 in CD34+/CD38- and CD34+/CD38+ chronic phase CML cells and in CD34+/CD38- normal haematopoietic cells.

To date, the epigenetic landscape in chronic myeloid leukaemia is poorly defined. Here we describe genome-wide ChIP-sequencing profiles for the histone modifications H3K4me3, H3K27me1 and H3K27me3 in both primary normal haematopoietic cells and primary chronic phase CML cells. CD34+/CD38- (stem) and CD34+/CD38+ (progenitor) cells were isolated by flow cytometry from primary normal and CML samples. CML samples were obtained from peripheral blood obtained at the point of diagnosis prior to tyrosine kinase inhibitor treatment. Normal (i.e., non-CML) samples were obtained by granulocyte-colony stimulating factor (G-CSF) mobilisation from individuals negative for bone marrow involvement upon lymphoma staging or from normal cadaveric bone marrow (BM) samples. H3K4me3 (Abcam, ab8580), H3K27me1 (Millipore, 07-448), H3K27me3 (Millipore, 07-449) ChIPs were performed using between 104-106 primary leukaemic stem cells (CD34+/CD38-) or leukaemic progenitor cells (CD34+/CD38+) or using 104 primary normal stem cells (CD34+/CD38-) as starting material with no pre-clearing of chromatin (n=3 bioreplicates for all cell types). ChIP-sequencing libraries were prepared according to manufacturer’s protocols (Illumina) with an average insert size of between 200-300 bp. ChIP-sequencing was performed in singlicate for each bioreplicate. Read lengths of 76 bp were obtained for each ChIP-sequencing library.